Guangzhou Key Laboratory for Clinical Rapid Diagnosis and Early Warning of Infectious Diseases, Kingmed School of Laboratory Medicine, Guangzhou Medical University, Guangzhou, 511436, China.
Faculty of Chinese Medicine, State Key Laboratory of Quality Research in Chinese Medicines, Macau University of Science and Technology, Taipa, China; Department of Ultrasound Medicine, Liwan Central Hospital of Guangzhou, 35 Liwan Road, Guangzhou, 510000, Guangdong, China.
J Ethnopharmacol. 2024 Nov 15;334:118521. doi: 10.1016/j.jep.2024.118521. Epub 2024 Jul 3.
Sangju Cold Granule (SJCG) is a classical traditional Chinese medicine (TCM) prescription described in "Item Differentiation of Warm Febrile Diseases". Historically, SJCG was employed to treat respiratory illnesses. Despite its popular usage, the alleviating effect of SJCG on influenza A virus infection and its mechanisms have not been fully elucidated.
Influenza is a severe respiratory disease that threatens human health. This study aims to assess the therapeutic potential of SJCG and the possible molecular mechanism underlying its activity against influenza A virus in vitro and in vivo.
Ultrahigh-performance liquid chromatography (UPLC)-Q-Exactive was used to identify the components of SJCG. The 50% cytotoxic concentration of SJCG in MDCK and A549 cells were determined using the CCK-8 assay. The activity of SJCG against influenza A virus H1N1 was evaluated in vitro using plaque reduction and progeny virus titer reduction assays. RT-qPCR was performed to obtain the expression levels of inflammatory mediators and the transcriptional regulation of RIG-I and MDA5 in H1N1-infected A549 cells. Then, the mechanism of SJCG effect on viral replication and inflammation was further explored by measuring the expressions of proteins of the RIG-I/NF-kB/IFN(I/III) signaling pathway by Western blot. The impact of SJCG was explored in vivo in an intranasally H1N1-infected BALB/c mouse pneumonia model treated with varying doses of SJCG. The protective role of SJCG in this model was evaluated by survival, body weight monitoring, lung viral titers, lung index, lung histological changes, lung inflammatory mediators, and peripheral blood leukocyte count.
The main SJCG chemical constituents were flavonoids, carbohydrates and glycosides, amino acids, peptides, and derivatives, organic acids and derivatives, alkaloids, fatty acyls, and terpenes. The CC of SJCG were 24.43 mg/mL on MDCK cells and 20.54 mg/mL on A549 cells, respectively. In vitro, SJCG significantly inhibited H1N1 replication and reduced the production of TNF-α, IFN-β, IL-6, IL-8, IL-13, IP-10, RANTES, TRAIL, and SOCS1 in infected A549 cells. Intracellularly, SJCG reduced the expression of RIG-I, MDA5, P-NF-κB P65 (P-P65), P-IκBα, P-STAT1, P-STAT2, and IRF9. In vivo, SJCG enhanced the survival rate and decreased body weight loss in H1N1-infected mice. Mice with H1N1-induced pneumonia treated with SJCG showed a lower lung viral load and lung index than untreated mice. SJCG effectively alleviated lung damage and reduced the levels of TNF-α, IFN-β, IL-6, IP-10, RANTES, and SOCS1 in lung tissue. Moreover, SJCG significantly ameliorated H1N1-induced leukocyte changes in peripheral blood.
SJCG significantly reduced influenza A virus and virus-mediated inflammation through inhibiting the RIG-I/NF-kB/IFN(I/III) signaling pathway. Thus, SJCG could provide an effective TCM for influenza treatment.
桑菊感冒颗粒(SJCG)是《温病条辨》中记载的一种经典的中药方剂。历史上,SJCG 被用于治疗呼吸系统疾病。尽管它的应用广泛,但 SJCG 对甲型流感病毒感染的缓解作用及其机制尚未完全阐明。
流感是一种严重的呼吸道疾病,威胁着人类健康。本研究旨在评估 SJCG 的治疗潜力及其在体外和体内对甲型流感病毒活性的可能分子机制。
采用超高效液相色谱-四级杆静电场轨道阱高分辨质谱联用(UPLC-Q-Exactive)技术对 SJCG 的成分进行鉴定。采用 CCK-8 法测定 SJCG 在 MDCK 和 A549 细胞中的 50%细胞毒性浓度(CC)。采用噬斑减少和子代病毒滴度降低试验评估 SJCG 对甲型流感病毒 H1N1 的体外活性。采用 RT-qPCR 检测 H1N1 感染的 A549 细胞中炎症介质的表达水平,以及 RIG-I 和 MDA5 的转录调控。然后,通过 Western blot 进一步检测 SJCG 对 RIG-I/NF-kB/IFN(I/III)信号通路中蛋白质表达的影响,以探索 SJCG 对病毒复制和炎症的作用机制。采用不同剂量 SJCG 处理滴鼻感染甲型流感病毒的 BALB/c 小鼠肺炎模型,研究 SJCG 的体内作用。通过生存、体重监测、肺病毒滴度、肺指数、肺组织学变化、肺炎症介质和外周血白细胞计数来评估 SJCG 在该模型中的保护作用。
SJCG 的主要化学成分是黄酮类、碳水化合物和糖苷、氨基酸、肽及其衍生物、有机酸及其衍生物、生物碱、脂肪酸和萜类化合物。SJCG 在 MDCK 细胞和 A549 细胞上的 CC 分别为 24.43mg/mL 和 20.54mg/mL。体外,SJCG 显著抑制 H1N1 复制,并降低感染 A549 细胞中 TNF-α、IFN-β、IL-6、IL-8、IL-13、IP-10、RANTES、TRAIL 和 SOCS1 的产生。细胞内,SJCG 降低了 RIG-I、MDA5、P-NF-κB P65(P-P65)、P-IκBα、P-STAT1、P-STAT2 和 IRF9 的表达。体内,SJCG 提高了 H1N1 感染小鼠的存活率并降低了体重减轻。与未治疗的小鼠相比,用 SJCG 治疗的 H1N1 诱导肺炎的小鼠肺病毒载量和肺指数较低。SJCG 可有效减轻肺损伤并降低肺组织中 TNF-α、IFN-β、IL-6、IP-10、RANTES 和 SOCS1 的水平。此外,SJCG 可显著改善 H1N1 诱导的外周血白细胞变化。
SJCG 通过抑制 RIG-I/NF-kB/IFN(I/III)信号通路,显著降低了甲型流感病毒及其介导的炎症。因此,SJCG 可以为流感治疗提供一种有效的中药。